HypoSkin®

SKIN MODEL FOR SUBCUTANEOUS INJECTIONS

NEW SUBCUTANEOUS INJECTIONS STUDY MODEL

HypoSkin is currently the only alternative to animal testing for subcutaneous injections.

INJECTABLE REAL HUMAN SKIN

The HypoSkin model contains all three layers of human skin for predictive studies.

LIVE HUMAN SKIN RESPONSE

Genoskin’s patented matrix and culture medium keep the skin model alive for up to 7 days.

ADAPTED TO YOUR NEEDS

HypoSkin is available in different formats and can be used for subcutaneous and topical applications.

close-up view of subcutaneous injections model HypoSkin®

The only human skin model to study subcutaneous injections

Genoskin is developing an ex vivo human skin biopsy with fat tissue. HypoSkin contains the three layers of the skin: epidermis, dermis and hypodermis. Currently, many of the compounds that are under development or already on the market are administrated subcutaneously, such as cancer treatments, anti-inflammatory agents or cosmetic fillers. HypoSkin is an ex vivo model to study compound absorption, first-pass catabolism and toxicity in the subcutaneous tissue.

Request our user manual
European flag

The HypoSkin project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 816289 (SME Instrument)

HypoSkin

a human in vitro model for subcutaneous injections

The HypoSkin model contains donated human skin tissue from abdominal surgery. The three compartments of the skin are preserved and placed in a culture insert that contains Genoskin’s patented biological matrix. The matrix and the culture medium allow to maintain the skin alive for at least 7 days.

Macroscopic view of adipose tissue models subcutaneous injections HypoSkin®

The need for in vitro models for subcutaneous injections

To date, there are no in vitro biological models to test the effects of compound injection in the subcutaneous tissue. Formulations are generally tested in vivo on animals, even though their skin and subcutaneous fat tissue are different from humans. The absence of more pertinent models makes it difficult to evaluate and optimize a compound’s formulation before clinical trials. To develop efficient drugs for subcutaneous injection, there’s a strong need for in vitro experimental models that closely mimic human tissue structure and physiology.

Hypo-InflammaSkin

a proof-of-concept case study

The HypoSkin technology was combined with the InflammaSkin model to evaluate the efficacy of subcutaneous psoriasis biologics adalimumab.

Read more
Close up of psoriasis biologics adalimumab for subcutaneous injections

HypoSkin® comes in different sizes and thickness to meet any study need

HypoSkin® comes in a range of formats varying in biopsy diameter and fat tissue thickness to assess skin response to subcutaneous injection and topical or systemic administration.

Please note that the successful use of HypoSkin® assays requires training. We would be happy to discuss it with you and help your project move forward: contact us for additional information.

   SUBCUTANEOUS INJECTIONTOPICAL ADMINISTRATION    
REFERENCEDESCRIPTIONØHYPODERMIS THICKNESSRECOMMENDED INJECTION VOLUMEWORKING SURFACERECOMMENDED TOPICAL VOLUMEEX VIVO CULTURE DURATIONPLATE FORMATREQUIRED VOLUME OF MEDIUM/DAYMINIMUM ORDER
HPS001-5HypoSkin®11 mm5 mm-0.5 cm25-20 uL7 days12 wells1 mL12 wells
HPS001-1010 mm20 uL
HPS002-5HypoSkin® Medium15 mm5 mm-1.13 cm225-45 uL7 days6 wells2 mL12 wells
HPS002-1010 mm40 uL
HPS003-5HypoSkin® Large20 mm5 mm-1.76 cm250-70 uL7 days6 wells2 mL12 wells
HPS003-1010 mm100 uL
HPS004-5HypoSkin® XL23 mm5 mm-2.54 cm2100-200 uL5 days6 wells3 mL12 wells
HPS004-1010 mm125 uL